Document is current
Any future updates will be listed below
-
Authors
Hørsdal, Oskar Kjærgaard
Moeslund, Niels
Berg-Hansen, Kristoffer
Nielsen, Roni
Møller, Niels
Eiskjær, Hans
Wiggers, Henrik
Gopalasingam, Nigopan
-
Funding
Funding for this research was provided by:
Danmarks Frie Forskningsfond (8020‐00120A)
Novo Nordisk Fonden (NNF17OC0028230, NNF21SA0069371)
Aase og Ejnar Danielsens Fond (00)
Direktør Emil C. Hertz og Hustru Inger Hertz Fond (00)
- License Information
-
More Information
Article History
Received: 6 November 2023
Accepted: 5 March 2024
First Online: 16 March 2024
Declarations
:
: This study was approved by the Danish Animal Experiment Inspectorate (permit number: <i>2021-15-0201-00853</i>). The care and handling of the animals were in accordance with Danish and European laws, guidelines and regulations on animal welfare and with the 1964 Helsinki Declaration and its later amendments. The performance of the study and the use of animals conformed with EU Directive 2010/63/EU on animal experiments. The study complied with the PREPARE guidelines [CitationRef removed] on study planning and the ARRIVE 2.0 guidelines [CitationRef removed] on study reporting. All pigs were humanely euthanised with pentobarbital by study end.
: Not applicable.
: Dr. Wiggers has been the principal or a sub-investigator in studies involving the following pharmaceutical companies: MSD, Bayer, Daiichi-Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis, and Pfizer. The other authors have no conflicts of interest to report. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
